Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Therapy

Spleen tyrosine kinase inhibitors—novel therapies for RA?

Nature Reviews Rheumatology volume 7, pages 134–136 (2011)Cite this article

Subjects

In patients with active rheumatoid arthritis despite therapy with DMARDs, treatment with a spleen tyrosine kinase inhibitor has achieved similar response rates to those achieved in clinical trials of other drugs, including biologic agents. Where might these agents fit in the current armamentarium against this disease?

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Weinblatt, M. E. et al. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N. Engl. J. Med. 363, 1303–1312 (2010).

    Article  CAS  Google Scholar 

  2. Weinblatt, M. E. et al. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum. 58, 3309–3318 (2008).

    Article  CAS  Google Scholar 

  3. Genovese, M. C. et al. An oral syk kinase inhibitor in the treatment of rheumatoid arthritis: a 3 month randomized placebo controlled phase 2 study in patients with active RA who had failed biologic agents. Arthritis Rheum. doi:10.1002/art.30114.

  4. McInnes, I. B. & O'Dell, J. R. State-of-the-art: rheumatoid arthritis. Ann. Rheum. Dis. 69, 1898–1906 (2010).

    Article  CAS  Google Scholar 

  5. Riccaboni, M., Bianchi, I. & Petrillo, P. Spleen tyrosine kinases: biology, therapeutic targets and drugs. Drug Discov. Today 15, 517–530 (2010).

    Article  CAS  Google Scholar 

  6. Bajpai, M., Chopra, P., Dastidar, S. G. & Ray, A. Spleen tyrosine kinase: a novel target for therapeutic intervention of rheumatoid arthritis. Expert Opin. Investig. Drugs 17, 641–659 (2008).

    Article  CAS  Google Scholar 

  7. Bahjat, F. R. et al. An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus Arthritis Rheum. 58, 1433–1444 (2008).

    Article  CAS  Google Scholar 

  8. Pine, P. R. et al. Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor. Clin. Immunol. 124, 244–257 (2007).

    Article  CAS  Google Scholar 

  9. Rivera, J. & Colbert, R. A. Healing the Syk through kinase inhibitors. N. Engl. J. Med. 363, 1362–1364 (2010).

    Article  CAS  Google Scholar 

  10. Jabbour, E., Deininger, M. & Hochhaus, A. Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia doi:10.1038/leu.2010.215.

Download references

Acknowledgements

The authors would like to thank R. Sanmartí for his critical appraisal of the article and D. Buss for his technical assistance.

Author information

Authors and Affiliations

  1. Department of Rheumatology, Arthritis Unit, Hospital Clínic, Villarroel 170, 08036, Barcelona, Spain

    José A. Gómez-Puerta

  2. Department of Internal Medicine, Hospital Clínic, Villarroel 170, 08036, Barcelona, Spain

    Xavier Bosch

Authors
  1. José A. Gómez-Puerta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xavier Bosch
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xavier Bosch.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gómez-Puerta, J., Bosch, X. Spleen tyrosine kinase inhibitors—novel therapies for RA?. Nat Rev Rheumatol 7, 134–136 (2011). https://doi.org/10.1038/nrrheum.2011.8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrrheum.2011.8

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing